Zansors Secures Issued Patent for Health Monitoring; New IP Enables Remote Detection of Health Anomalies

ARLINGTON, VA. (March 26, 2019) – Zansors, a wearable tech company based in Northern, Virginia, has added to its growing collection of patents. Zansors was recently awarded a patent for a wearable patch to automatically monitor, screen and/or report health conditions. Zansors’ next-generation intellectual property (IP) will allow health monitoring devices to detect sleeping or breathing disorders.

 “Zansors is developing and bringing to market, small, wearable and easy-to-use devices that will represent the next generation in sleep apnea and lifestyle technologies. This latest patent represents an important step in implementing our devices into the daily life of our customers,” said Abhijit Dasgupta, Ph.D., inventor of the patent and Co-Founder and Chief Data Science Officer at Zansors.

This system for monitoring conditions can also be used to monitor and diagnose other medical conditions such as, but not limited to, asthma, pneumonia, chronic obstructive pulmonary disease (COPD), congestive heart failure, arrhythmias, restless leg syndrome, seizures, falls, metabolic/nutritional levels (e.g. glucose and lipid monitoring) and sudden infant death syndrome (SIDS). Several wellness and fitness conditions can be monitored besides health conditions such as physical activity monitoring (ventilatory threshold, intensity and type, calorie expenditure, and sedentary vs. activity analysis), baby monitoring, from breaths.

This utility patent focuses on health monitoring via a wearable biosensor by employing algorithm and signal processing methods for physiological signals. Zansors was also previously issued a patent for specialized protecting adhesive to be used for wearable health sensor patches. These patents underpin the path to commercialization for Zansors’ R&D investments in wearable tech.

 “Zansors is creating a future that allows remote detection of several health conditions that can be currently monitored only in a clinical setting. Linking subjective information from a mobile application with objective data using this system can provide a holistic picture of health, wellness and activity of the individual,” said Dasgupta. “Zansors’ wearable health tech is going to change how well you ‘know yourself’.”

 Zansors’ new patent will lead to monitoring capability in the hands of consumers who can be empowered to monitor more of their health conditions on a continuous basis, instead of episodic screening in a clinical lab setting.

“The advancement in wearable biosensor technology can be further accelerated by innovations in signal processing for diagnostic purposes,” said Dale Lazar of DLA Piper, a global law firm. “The patent granted by the United States proves that Zansors is innovating effectively.” DLA Piper’s Reston, Virginia office supported patent prosecution.

For more information on this patent, view the summary. Learn more about Zansors’ technologies at www.zansors.com, where you can sign up for email updates, and follow us on Facebook and Twitter.

 About Zansors

Zansors is a Washington, DC metro-based healthcare innovation company delivering personal health analytics into the hands of consumers via wearable bio-sensors and health apps. Driven by our credo of “know yourself,” Zansors combines evidence-based apps, bioengineering and data analytics, allowing consumers to take charge of their health. Our proprietary biotechnology platform includes micro-sensors and micro-fluidics (also known as “lab-on-a-chip”) backed by a strong portfolio of patents filed. Zansors has previously received funding awards by NIH.

Zansors Wins NIH Grant to Advance Wearable At-Home Affordable Sleep Apnea Detection

This additional, larger, Phase II grant from National Institutes of Health will continue support of research and commercialization of Zansors’ “first to market” wearable consumer sleep-apnea product

Arlington, VA. (January 25, 2017) -- Zansors, a healthcare innovation company focused on wearable bio-sensors and health apps, was awarded $1.5 million by the NIH's National Institute on Minority Health and Health Disparities (NIMHD) for Phase II of their SBIR/STTR program. This is a continuation of a previously funded Phase I grant and is Zansors’ sixth grant win from NIH.

The funds will be used to further develop research and then seek FDA approval for a wearable sleep product to screen for sleep apnea. This would be a wireless, wearable, over the counter sleep apnea product. More than 18 million adult Americans have sleep apnea, according to the National Sleep Foundation. Up to 80 percent of these cases may be undiagnosed.  Untreated sleep apnea can lead to conditions from hypertension and heart disease to tiredness and depression.

“With this funding, our aim is to significantly increase the screening of at-risk, under-served individuals by making diagnosis easy and affordable for all.” said Todd Arnedt, PhD, Director of the Insomnia and Behavioral Sleep Medicine Program, University of Michigan.

Dr. Arnedt will serve as Principal Investigator for the grant, and University of Michigan will have a significant role in this research. Abhijit Dasgupta, PhD, Co-founder and Chief Data Science Officer of Zansors, will serve as Co-Investigator.

“We are using our technology to combine wearable sensors, algorithms and bioengineering into a first of its kind product,” said Dr. Dasgupta. “The process to create this sleep apnea screening device is complex, but the idea is simple: Zansors making affordable, easy-to-use diagnostic tools so people can be proactive about their health. You can’t improve yourself without first identifying the issues.”

Phase I research on this sleep apnea device assessed feasibility, and the device was tested on 50 patients at University of Michigan. This phase also demonstrated that the device performs well compared to gold-standard diagnostics for sleep apnea. These early positive results have helped Zansors gain support from leading healthcare institutions, including Kaiser Permanente and Inova Health System.

Phase II, which is currently in progress, will focus on validation, beginning with improving the design and bio-engineering of the device and developing more efficient and accurate algorithms.

“This technology not only holds promise for helping Americans detect sleep apnea, it also has great potential to decrease costs in healthcare,” said Mark Fendrick, MD, Professor of Internal Medicine and Health Management and Policy, and Director of the Center for Value-Based Insurance Design at the University of Michigan. “The research that NIMHD is funding is exactly what is needed to introduce a more effective way of delivering care.”

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this press release was supported by National Institute on Minority Health and Health Disparities of the National Institutes of Health under award number: 2R42MD008845-02.

About Zansors

Zansors is a Washington, DC metro-based healthcare innovation company focused on wearable bio-sensors and health apps. Driven by our credo of “know yourself”, Zansors combines evidence-based apps, bio-engineering and data analytics, allowing consumers to take charge of their health. Our proprietary biotechnology platform includes micro-sensors and micro-fluidics (also known as “lab-on-a-chip”) backed by a strong portfolio of patents filed. Zansors has previously received 5 funding awards by NIH and has formal partnerships with the University of Michigan and George Washington University.

Zansors’ Chief Data Science Officer to speak at mHealth Summit 2014

Tysons, VA, December 3, 2014 -- Zansors’ Chief Data Science Officer Abhijit Dasgupta, PhD has been announced as a speaker at mHealth Summit 2014. Dr. Dasgupta will speak in the session Conditional Management with Mobile and Connected Health, on "Real-time monitoring of lymphedema using self-reporting, sensors and mobile technologies".

Dr. Dasgupta is the lead scientist on Zansors Cancer Survivor Symptom Tracker, a project funded by the National Cancer Institute’s (NCI) SBIR Contract Program. Women who have undergone surgery or radiation for breast cancer are prone to lymphedema, swelling caused by fluid retention in the lymph nodes. Often they don’t see their doctors until symptoms become debilitating. Zansors Cancer Survivor Symptom Tracker allows these women to:

• Quickly and easily input data on symptoms and quality of life on their smart phones or tablets
• Send data to caregivers, from mobile devices and wearable sensors, using a HIPAA-compliant cloud-based system
• Receive encouraging prompts to collect data or notifications to “see doctor,” before a crisis develops
• Communicate complete health stories—as opposed to relying on memory during short, sporadic doctor visits

Dr. Dasgupta’s Co-Principal Investigator is Kathryn H. Schmitz, PhD, MPH, Professor of Epidemiology in Biostatistics and Epidemiology at the University of Pennsylvania Perelman School of Medicine.

What: Conditional Management with Mobile and Connected Health

When: Monday, 12/08/2014 11:00AM -12:00PM

Where: Room National Harbor 10-11

About Zansors

With our credo of “know yourself” Zansors® endorses a patient-centric health model. We believe that better health and wellness comes only when you know your health habits and symptoms, as they occur over time – not just when you see your doctor. Our evidence-based apps, sensors and digital tracking tools empower you to collect personal health data easily and affordably. So your health care decisions become clear, accurate, and relevant — based on you, not on someone like you. For more information please click here.

About the Conference

The largest event of its kind, the mHealth Summit gathers a uniquely diverse international delegation, including healthcare technology officials in government and industry; policymakers; academic researchers and students; healthcare providers; entrepreneurs; investors; public health and safety officials and patient advocates from across mobile and connected health. For additional information please click here.

Zansors to Co-Present at the Next Generation Dx Summit

Baabi Das, Founder and President of Zansors, will be co-presenting a session on Enabling Point-of-Care Diagnostics at the Next Generation Dx Summit with Zhenyu Li, Ph.D., Assistant Professor, School of Engineering and Applied Science, George Washington University on Tuesday, August 19th 2014. The pair will present and discuss recent microfluidic technology developments in the laboratories of George Washington University that are being commercialized by Zansors to offer next-generation tools for realizing both medical tricorder-like handheld in vitro diagnostic (IVD) systems and wearable lab-on-a-chip systems. Additionally a fully automated handheld immunoassay system will be discussed as well as a bendable, stretchable microfluidic system based on oxidative stress and other biomarkers.

Zhenyu Li, Ph.D., focuses his work on the integration of nanophotonics and microfluidics, or Optofluidics, for life sciences and medicine, particularly single cell analysis for stem cell and cancer research, and portable integrated biosensors for point-of-care diagnostics, environmental monitoring and food safety inspection. He earned his Ph.D. in Electrical Engineering from the California Institute of Technology.

About the Next Generation Dx Summit

Access to next generation diagnostics will only be gained through careful creation and management of partnerships in the community around development, commercialization, reimbursement and regulation. This year’s Next Generation Dx Summit will showcase advances in personalized medicine through a comprehensive program encompassing companion diagnostics, infectious disease, cancer molecular markers, point-of-care, inherited disorders, cell-free DNA and single-cell sequencing. This event has become the meeting place for major players in the expanding arena of diagnostics. It will showcase key components of their successful adoption in the clinic and advancement to the market.

Zansors Named a Semifinalist in LIVESTRONG Foundation’s Inaugural Big C Competition

TYSONS, VA | June 5, 2014 – Zansors selected as a semi-finalist for the 2014 Big C Competition powered by LIVESTRONG

The Big C, powered by LIVESTRONG, announced that Zansors has been selected as a semi-finalist from a field of more than 750+ entries. The Big C is a one-of-a-kind competition to generate innovations that improve the quality of life for the 32.5 million people worldwide living with cancer.

Zansors’ submission is platform including a patient app and clinician dashboard that digitally monitors patient quality of life for breast cancer survivors. It captures patient self-reported data as well as behavioral and lifestyle indicators relevant to lymphedema, and combines this with data collected from a wearable tracking sensor.

"I'm delighted with the response we're getting to this platform,” said Jill MacNeice, Zansors Chief Experience Officer. “We are committed to improving outcomes for cancer survivors. Digital self-tracking, which can be done easily and in the moment, is an important tool to help survivors gain a better quality of life."

Semi-Finalists are competing for $140,000 in seed funding, mentoring and global exposure to a community of potential customers and investors to develop programs, services, new technology and inventions that improve cancer patients' and survivors' daily life.

"The Big C Competition has the potential to bring our platform to survivors of other types of cancer and to those facing other diseases on a much quicker timeline," said Jason Waxberg, Zansors Chief Growth Officer. "Knowing that our evidence based, patient-centric solutions can improve a patient's quality of life is a powerful motivator for us not only in this competition but in everything we do."

The Big C will announce the companies moving on to the next round on July 14.

About Zansors

With our credo of “know yourself” Zansors® endorses a patient-centric health model. We believe that better health and wellness comes only when you know your health habits and symptoms, as they occur over time – not just when you see your doctor. Our evidence-based apps, sensors and digital tracking tools empower you to collect personal health data easily and affordably. So your health care decisions become clear, accurate, and relevant —based on you, not on someone like you. For the latest news be sure to follow Zansors on twitter.

About the LIVESTRONG Foundation

The LIVESTRONG Foundation fights to improve the lives of people affected by cancer now. Created in 1997, the Foundation is known for providing free cancer support services and advocating for policies that improve access to care and quality of life. Known for its powerful brand – LIVESTRONG – the Foundation has become a symbol of hope and inspiration around the world. Since its inception, the Foundation has served 2.5 million people affected by the disease and raised more than $500 million to support cancer survivors. One of America's top non-profit organizations, the Foundation has been recognized by industry leaders including Charity Navigator, the National Health Council and the Better Business Bureau for its excellent governance, high standards and transparency. For more information, visit LIVESTRONG.org.

Zansors has been named a finalist at AARP Health Innovation @50+ LivePitch

We’re proud to announce that Zansors has been named a finalist at next month's AARP Health Innovation @50+ LivePitch!

The event, held during AARP's Life@50+ AARP National Event & Expo, features Zansors and nine peer companies that are poised to make an impact in healthcare for those 50 and over – and for everyone.

Read the press release here: http://health50.org/2014/04/01/aarp-livepitch-startup-health-tech-finalists-announced/